DavidL.JayeMD

Hematopathology, Anatomic Pathology, Clinical Pathology

Assistant Professor, Pathology & Laboratory Medicine, Emory University School of Medicine

Dr. Jaye is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
615 Michael St NE
Rm 105-B
Atlanta, GA 30322
Phone+1 404-712-2805

Fax+1 404-727-8538

Emory University School of MedicineFellowship, Hematopathology, 1997 - 1998
University of Alabama Medical CenterResidency, Pathology-Anatomic and Clinical, 1995 - 1997
Washington University/B-JH/SLCH ConsortiumResidency, Pathology-Anatomic and Clinical, 1991 - 1995
Washington University in St. Louis School of MedicineClass of 1991

PubMed

120 citations
Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone.
Timothy M. Schmidt, Benjamin G. Barwick, Nisha Joseph, Leonard T. Heffner, Craig C. Hofmeister
Blood Cancer Journal. 2019-11-25
219 citations
Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target.
Dharminder Chauhan, Ajita V. Singh, Mohan Brahmandam, Ruben D. Carrasco, Madhavi Bandi
Cancer Cell. 2009-10-06
483 citations
A New Immunostain Algorithm Classifies Diffuse Large B-Cell Lymphoma into Molecular Subtypes with High Accuracy
William W.L. Choi, Dennis D. Weisenburger, Timothy C. Greiner, Miguel A. Piris, Alison H. Banham
Clinical Cancer Research. 2009-09-01

Abstracts/Posters

Utility and Patterns of Use of PET/CT and Bone Marrow Biopsy for Staging in Non-Hodgkin Lymphoma in the Clinical Setting: A Retrospective Analysis Using the LEO Database
David L. Jaye, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Whole Exome and Transcriptome Sequencing in 1042 Cases Reveals Distinct Clinically Relevant Genetic Subgroups of Follicular Lymphoma
David L. Jaye, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Vulnerable Elders Survey-13 (VES-13) Predicts 1-Year Mortality Risk in Newly Diagnosed Non-Hodgkin Lymphoma (NHL)
David L. Jaye, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

Outcomes of Myeloma Patients with Deletion 1p Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Therapy
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study Reflects the Demographics and Subtypes of Patients Diagnosed with Non-Hodgkin Lymphoma in the United States
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018